# Veranderingen in plaspatroon en kwaliteit van leven bij kinderen met plasproblemen die een behandeling met Botox krijgen.

No registrations found.

**Ethical review** Positive opinion

**Status** Pending

Health condition type -

**Study type** Observational non invasive

# **Summary**

#### ID

NL-OMON23220

Source

NTR

**Brief title** 

Change in voiding pattern after BoNT-A

**Health condition** 

Dysfunctional voiding.

### **Sponsors and support**

**Primary sponsor:** Erasmus MC

Source(s) of monetary or material Support: None.

Intervention

#### **Outcome measures**

#### **Primary outcome**

PVR, defined as volume of residual urine in the bladder after voluntary voiding determined

1 - Veranderingen in plaspatroon en kwaliteit van leven bij kinderen met plasproblem ... 5-05-2025

through ultrasound, after treatment at predetermined time points compared to baseline.

#### **Secondary outcome**

Results after treatment compared to baseline determined at predetermined time points:

- Incontinence episodes per day derived from the voiding diary
- 24 hour frequency derived from the voiding diary
- Number of UTIs: clinical symptoms (pollakiuria, dysuria) combined with a positive dipstick for leucocytes or a positive urine culture
- Peak flow in ml/s derived from uroflowmetry
- Scores derived from the PINQ and Vancouver SSDES guestionnaires
- Duration of improvement of voiding pattern and quality of life

# **Study description**

#### **Background summary**

Dysfunctional voiding (DV) is a term used for nonneurogenic increased urethral sphincter or pelvic floor muscle activity during voluntary voiding. The result is a lack of coordination between the detrusor muscle and the urethral sphincter. This results in either symptoms of urinary incontinence (UI), urinary tract infections (UTIs), or high post-void residual (PVR). A substantial group of children with DV, 10-40%, remains therapy-refractory. This group of children currently receives BoNT-A injections in the external urethral sphincter at Erasmus MC - Sophia as standard care. In a retrospective analysis performed by the investigators of the current protocol BoNT-A treatment has shown to be an effective and safe treatment option.

Children will receive BoNT-A treatment as standard care. Changes in voiding pattern and quality of life will be determined at predetermined time points based on uroflowmetry, dipstick analysis, PVR determination, voiding diaries, and questionnaires.

This patient group has an average of 6 outpatient visits per year as part of standard care. During the last study visit they will perform an extra uroflowmetry and keep a voiding diary for two days similar to the other five outpatient visits. Patients will be asked to fill out two

questionnaires, which are not part of standard care, at seven time points. They are asked to keep a voiding diary for two days at seven time points, including for telephone contact. This is one extra time compared to standard care.

#### **Study objective**

To assess the change in voiding pattern and quality of life in children who receive BoNT-A treatment in a prospective setting.

#### Study design

Baseline, 2 weeks after baseline, week 0, week 2, week 6, 3 months, 6 months, 9 months, 12 months.

#### Intervention

Not applicable: study is observational.

### **Contacts**

#### **Public**

L.A. Hoen, 't Dept. Urology, room Na-17 Erasmus MC Wytemaweg 80 Rotterdam 3015 CN The Netherlands 010 - 703 65 59

#### Scientific

L.A. Hoen, 't Dept. Urology, room Na-17 Erasmus MC Wytemaweg 80 Rotterdam 3015 CN The Netherlands 010 - 703 65 59

# **Eligibility criteria**

### **Inclusion criteria**

- Male or female children aged 5-12 years
- Has therapy-refractory DV and the next step in treatment is BoNT-A injection
- Has received a minimum of five sessions of urotherapy
- Has received a minimum of two sessions of pelvic floor muscle physical therapy
- Signed informed consent

#### **Exclusion criteria**

- Has anatomic abnormalities of the urinary tract
- Patients who have received additional treatment:
- o BoNT-A injections in the detrusor muscle
- o Appendicovesicostomy
- o Bladder augmentation
- Has a neurogenic disorder
- Has a neuromuscular disorder
- Has a psychological disorder
- Uses products that influence neuromuscular transmission

# Study design

### **Design**

Study type:

Observational non invasive

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-08-2014

Enrollment: 30

Type: Anticipated

# **Ethics review**

Positive opinion

Date: 02-07-2014

Application type: First submission

# **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register ID

NTR-new NL4530 NTR-old NTR4665

Other METC 2014-223 : OZBS62.14009

Study results	